Organization
BostonGene Corporation
9 abstracts
Abstract
The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast.Org: BostonGene Corporation, BostonGene Corp., The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, BostonGene, Corp.,
Abstract
A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma.Org: Washington University School of Medicine in St. Louis, Mayo Clinic, Washington University in St. Louis, BostonGene, Corp., BostonGene Corporation,
Abstract
An unsupervised H&E-based machine-learning approach for precise prediction of tumor microenvironment subtypes.Org: BostonGene Corporation, Corp.,
Abstract
Aggregated analysis of 1,000 patients with cancer to assess the benefits of integrated whole exome and whole transcriptome sequencing.Org: BostonGene Corporation, Waltham, MA, MaaT Pharma, Corp.,
Abstract
Genomic characterization of the GATA3 mutational landscape in breast cancer.Org: University of Texas MD Anderson Cancer Center, BostonGene Corporation, BostonGene Corp.,
Abstract
Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.Org: University of Texas MD Anderson Cancer Center, BostonGene Corporation, BostonGene, Corp.,
Abstract
Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.Org: Sarcoma Oncology Research Center, Santa Monica, CA, Santa Monica, CA, Dornsife College of Letters, University of Southern California, Los Angeles, CA, University of California Los Angeles,
Abstract
Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.Org: BostonGene, Corp., Waltham, MA, BostonGene Corporation, University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Tumor immunity portrait: An AI-driven molecular predictor combining tumor microenvironment and tumor mutational burden for immune checkpoint inhibitor response prediction.Org: BostonGene Corporation, Corp.,